A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein-Barr virus.

Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99

Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening. Expert Opin Drug Discov (2010) 0.75

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J Virol (2004) 1.98

EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog (2006) 1.71

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71

Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol (2005) 1.59

Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J Virol (2004) 1.57

The relationship between motor deficit and hemisphere activation balance after stroke: A 3T fMRI study. Neuroimage (2006) 1.55

A model for neuronal competition during development. Science (2008) 1.52

Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther (2009) 1.52

Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat Protoc (2012) 1.51

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res (2007) 1.47

Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol (2005) 1.47

Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A (2005) 1.45

Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma (2004) 1.44

Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol (2003) 1.43

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2009) 1.42

The activity-dependent transcription factor NPAS4 regulates domain-specific inhibition. Nature (2013) 1.41

A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKε. Cell Res (2011) 1.40

MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages. J Immunol (2010) 1.38

Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett (2003) 1.37

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol (2006) 1.36

Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature. Leuk Lymphoma (2006) 1.35

Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J Virol (2006) 1.33

Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol (2006) 1.30

miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One (2011) 1.29

Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res (2005) 1.28

Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. J Virol (2002) 1.26

Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One (2009) 1.26

Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res (2011) 1.25

Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol (2004) 1.21

Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention. Cancer Biol Ther (2010) 1.19

A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol (2007) 1.19

Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol (2009) 1.18

Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology (2009) 1.18

SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol (2005) 1.17

Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood (2004) 1.16

Kaposi's sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J Virol (2011) 1.15

Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology (2007) 1.14

Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One (2010) 1.12

A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol (2004) 1.10

Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci U S A (2008) 1.09

Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res (2010) 1.09

Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol (2008) 1.08

Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum (2003) 1.07

Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog (2011) 1.07

ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. J Virol (2003) 1.07

Kaposi's sarcoma-associated herpesvirus RTA activates the processivity factor ORF59 through interaction with RBP-Jkappa and a cis-acting RTA responsive element. Virology (2008) 1.05

Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol (2006) 1.04

The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. J Virol (2002) 1.04

Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One (2010) 1.04

Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation. J Virol (2009) 1.03

Motor imagery to enhance recovery after subcortical stroke: who might benefit, daily dose, and potential effects. Neurorehabil Neural Repair (2008) 1.02

The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol (2007) 1.02

Sex differences in vasopressin V₂ receptor expression and vasopressin-induced antidiuresis. Am J Physiol Renal Physiol (2010) 1.02

Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J Virol (2007) 1.02

Posttransplant lymphoproliferative disorder. Ann Pharmacother (2007) 1.01

The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog (2013) 1.00

The management of posttransplant lymphoproliferative disorder. Med Oncol (2007) 1.00

H2AX phosphorylation is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome persistence. J Virol (2013) 1.00

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats. J Virol (2006) 0.99

Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology (2010) 0.98

Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro. J Virol (2006) 0.98

Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol (2008) 0.98

Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog (2011) 0.96

Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus recruits uracil DNA glycosylase 2 at the terminal repeats and is important for latent persistence of the virus. J Virol (2006) 0.96

The minimal replicator element of the Kaposi's sarcoma-associated herpesvirus terminal repeat supports replication in a semiconservative and cell-cycle-dependent manner. J Virol (2006) 0.96

The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection. J Virol (2011) 0.95

Molecular biology of Kaposi's sarcoma-associated herpesvirus. Front Biosci (2002) 0.95

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol (2012) 0.95

Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol (2010) 0.94

Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin. J Virol (2002) 0.94

Kaposi's sarcoma herpesvirus-encoded latency-associated nuclear antigen stabilizes intracellular activated Notch by targeting the Sel10 protein. Proc Natl Acad Sci U S A (2007) 0.93

The RBP-Jκ binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation. PLoS Pathog (2012) 0.93

KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology (2006) 0.93

EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol (2010) 0.93

Motor imagery ability in patients with early- and mid-stage Parkinson disease. Neurorehabil Neural Repair (2011) 0.92

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen reduces interleukin-8 expression in endothelial cells and impairs neutrophil chemotaxis by degrading nuclear p65. J Virol (2011) 0.92

The Epstein Barr nuclear antigen EBNA3C regulates transcription, cell transformation and cell migration. Front Biosci (2002) 0.92

A unique SUMO-2-interacting motif within LANA is essential for KSHV latency. PLoS Pathog (2013) 0.91

Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog (2012) 0.91

Serodiagnostic efficacy of Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex, ESAT-6, and CFP-10 in patients with active tuberculosis. Arch Immunol Ther Exp (Warsz) (2010) 0.91

Posttransplant lymphoproliferative disorder following kidney transplant. Am J Kidney Dis (2009) 0.91

Nm23-H1 modulates the activity of the guanine exchange factor Dbl-1. Int J Cancer (2008) 0.91

MicroRNAs and unusual small RNAs discovered in Kaposi's sarcoma-associated herpesvirus virions. J Virol (2012) 0.91